Emergent Biosolutions Inc (EBS) financials · rev $742.9M
Lician Pro · $19.99/mo or $149/yrCompare AAPL vs MSFT
Emergent Biosolutions Inc (EBS) rev $742.9M.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $742.9M | $1.04B |
| Cost of Revenue | $326.2M | $681.3M |
| Gross Profit | $416.7M | $362.3M |
| Operating Income | $100.1M | -$108.7M |
| Net Income | $52.6M | -$190.6M |
| EPS (Diluted) | $0.93 | -$3.60 |
| Line | FY2025 | FY2024 |
|---|---|---|
| Total Assets | $1.32B | $1.39B |
| Current Assets | $662.5M | $598.7M |
| Cash & Equivalents | $205.4M | $99.5M |
| Inventory | $343.4M | $311.7M |
| PP&E | $205.4M | $270.6M |
| Total Liabilities | $796.0M | $906.9M |
| Current Liabilities | $132.2M | $162.4M |
| Short-term Debt | N/A | N/A |
| Long-term Debt | $572.1M | $663.7M |
| Total Debt | $572.1M† | $663.7M† |
| Shareholders' Equity | $522.6M | $482.8M |
| Retained Earnings | -$159.8M | -$212.4M |
† Total Debt: Derived from long-term debt only (no total or short-term debt stored).
† Total Debt: Derived: short-term debt plus long-term debt (no total debt stored).
| Line | FY2025 | FY2024 |
|---|---|---|
| Operating Cash Flow | $170.6M | $58.7M |
| CapEx | $13.8M | $22.9M |
| Investing Cash Flow | $69.4M | $125.2M |
| Financing Cash Flow | -$136.6M | -$190.0M |
| Net Change in Cash | $103.5M | -$6.10M |
| Free Cash Flow | $156.8M | $35.8M |
FAQ
What is EBS P/E and revenue?
Emergent Biosolutions Inc (EBS) rev $742.9M.
What is EBS revenue?
Emergent Biosolutions Inc last cached revenue is $742.9M (FY2025).
Is EBS profitable?
Emergent Biosolutions Inc last cached net income is $52.6M (FY2025).
What are EBS total assets?
Emergent Biosolutions Inc last cached total assets are $1.32B (FY2025).
What is EBS free cash flow?
Emergent Biosolutions Inc last cached free cash flow is $156.8M (FY2025).
Not investment advice. Cached statements, not a live tape.